Skip to main content
Top
Published in: Inflammopharmacology 3/2019

01-06-2019 | Original Article

Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-κB pathways in B and T cells

Authors: Xinming Wang, Xiaoyun Chen, Wei Huang, Pengying Zhang, Yawei Guo, Heinrich Körner, Huaxun Wu, Wei Wei

Published in: Inflammopharmacology | Issue 3/2019

Login to get access

Abstract

The angiotensin II type 1 receptor (AT1R) antagonist losartan has been confirmed to have a moderate anti-inflammatory effect in vitro and in vivo. However, how it affects immune cells in Rheumatoid Arthritis (RA) is still unknown. We found that in human synovial tissues, AT1R is significantly expressed on T cells and B cells. Treatment with losartan (15 mg/kg) alone and in combination with a low dose of methotrexate (MTX 0.25 mg/kg/3 days) significantly suppressed the progression of CIA. Secondary paw swelling, joint destruction and the presence of pro-inflammatory cytokines (TNF-α and IFN-γ) in the serum were alleviated after treatment. The therapeutic effects of losartan were based on reduced T-cell and B-cell activation, specifically by decreased cell vitality and pro-inflammatory cytokine production. In addition, losartan combined with a low dose of MTX achieved a similar therapeutic effect, while protecting liver and kidney from MTX damage. Mechanistically, losartan inhibits the production of pro-inflammatory mediators, reduces the phosphorylation of p38, ERK, and p65, p50 nuclear transposition in T cells and B cells. Phosphorylation of JNK is not affected by losartan in the CIA rat model. losartan can be used as an effective RA treatment, which exhibits anti-arthritic effects potentially through down-regulating the phosphorylation of p38, ERK and signaling through NF-κB. While achieving similar anti-rheumatic effects, a combination therapy of losartan with a low dose of MTX, can protect from liver and renal damage caused by giving a high dose of MTX.
Literature
go back to reference Arnett FC et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed Arnett FC et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed
go back to reference Bird HA et al (1990) A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol 17:603–608PubMed Bird HA et al (1990) A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol 17:603–608PubMed
go back to reference Cheng ZJ, Vapaatalo H, Mervaala E (2005) Angiotensin II and vascular inflammation. Med Sci Monitor Int Med J Exp Clin Res 11:RA194–RA205 Cheng ZJ, Vapaatalo H, Mervaala E (2005) Angiotensin II and vascular inflammation. Med Sci Monitor Int Med J Exp Clin Res 11:RA194–RA205
go back to reference Latha RM, Geetha T, Varalakshmi P (1998) Effect of Vernonia cinerea Less flower extract in adjuvant-induced arthritis. General Pharmacol 31:601–606CrossRef Latha RM, Geetha T, Varalakshmi P (1998) Effect of Vernonia cinerea Less flower extract in adjuvant-induced arthritis. General Pharmacol 31:601–606CrossRef
go back to reference Martin MF, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V (1984) Captopril: a new treatment for rheumatoid arthritis? Lancet 1:1325–1328CrossRefPubMed Martin MF, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V (1984) Captopril: a new treatment for rheumatoid arthritis? Lancet 1:1325–1328CrossRefPubMed
go back to reference Price A, Lockhart JC, Ferrell WR, Gsell W, McLean S, Sturrock RD (2007) Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. Arthritis Rheum 56:441–447. https://doi.org/10.1002/art.22335 CrossRefPubMed Price A, Lockhart JC, Ferrell WR, Gsell W, McLean S, Sturrock RD (2007) Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. Arthritis Rheum 56:441–447. https://​doi.​org/​10.​1002/​art.​22335 CrossRefPubMed
go back to reference Walsh DA, Suzuki T, Knock GA, Blake DR, Polak JM, Wharton J (1994) AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol 112:435–442CrossRefPubMedPubMedCentral Walsh DA, Suzuki T, Knock GA, Blake DR, Polak JM, Wharton J (1994) AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol 112:435–442CrossRefPubMedPubMedCentral
go back to reference Zhai KF, Duan H, Luo L, Cao WG, Han FK, Shan LL, Fang XM (2017) Protective effects of paeonol on inflammatory response in IL-1beta-induced human fibroblast-like synoviocytes and rheumatoid arthritis progression via modulating NF-kappaB pathway. Inflammopharmacology 6:7. https://doi.org/10.1007/s10787-017-0385-5 CrossRef Zhai KF, Duan H, Luo L, Cao WG, Han FK, Shan LL, Fang XM (2017) Protective effects of paeonol on inflammatory response in IL-1beta-induced human fibroblast-like synoviocytes and rheumatoid arthritis progression via modulating NF-kappaB pathway. Inflammopharmacology 6:7. https://​doi.​org/​10.​1007/​s10787-017-0385-5 CrossRef
Metadata
Title
Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-κB pathways in B and T cells
Authors
Xinming Wang
Xiaoyun Chen
Wei Huang
Pengying Zhang
Yawei Guo
Heinrich Körner
Huaxun Wu
Wei Wei
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 3/2019
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-018-0545-2

Other articles of this Issue 3/2019

Inflammopharmacology 3/2019 Go to the issue